Gyros AB licenses patented technology to Fluidigm Corporation
Gyros AB and Fluidigm Corporation today announced finalization of a licensing agreement of a patent family held by Gyros which covers certain microfluidic devices based on elastomeric layers. The Gyros patent applies in the US and in additional major biotech markets worldwide.
Maris Hartmanis, President and CEO at Gyros AB explained, "We are very pleased that Fluidigm has agreed to become the initial licensee of one of Gyros' early patent filings. We expect that additional companies will also sign up for our licensing program."
Gajus Worthington, President and CEO of Fluidigm added, "this is great technology, and Fluidigm is delighted to have access to it."
Fluidigm has successfully commercialized the Topaz(TM) Crystallizer to automate the metering, mixing, and isolation of protein crystallization experiments. This system is enabled by a proprietary process known as Multi-layer Soft Lithography (MSL(TM)) to manufacture three-dimensional structures from multiple layers of soft elastomer. With this technology, Fluidigm intends to provide an increasing range of products for the biotechnology research market.
Hartmanis continued, "Gyros and Fluidigm are at the forefront in the development of their respective microfluidic technologies. It will be a fascinating journey as we produce more application solutions and see microfluidic-based technologies become standard in the world of drug discovery."
Other news from the department research and development
